Clodronate Reduces Vertebral Fracture Risk in Women With Postmenopausal or Secondary Osteoporosis: Results of a Double-Blind, Placebo-Controlled 3-Year Study-Reference-Cited by-同舟云学术

Clodronate Reduces Vertebral Fracture Risk in Women With Postmenopausal or Secondary Osteoporosis: Results of a Double-Blind, Placebo-Controlled 3-Year Study

Published:2004-01-19 Issue:5 Volume:19 Page:728-736
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

McCloskey Eugene,Selby Peter,Davies Mike,Robinson John,Francis Roger M,Adams Judith,Kayan Karthik,Beneton Monique,Jalava Tarja,Pylkkänen Liisa,Kenraali Juha,Aropuu Sakari,Kanis John A

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Reference38 articles.

1. Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis;Klotzbuecher;J Bone Miner Res,2000

2. Does a fracture at one site predict later fractures at other sites? A British Cohort Study;Van Staa;Osteoporos Int,2002

3. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer;Paterson;J Clin Oncol,1993

4. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults;McCloskey;Br J Haematol,1998

5. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer;Powles;J Natl Cancer Inst,1998

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-treatment bone mineral density and the benefit of pharmacologic treatment on fracture risk and BMD change: analysis from the FNIH-ASBMR SABRE project;Journal of Bone and Mineral Research;2024-05-01

2. Follow-up bone mineral density testing: 2023 official positions of the International Society for Clinical Densitometry;Journal of Clinical Densitometry;2024-01

3. Refracture following vertebral fragility fracture when bone fragility is not recognized: summarizing findings from comparator arms of randomized clinical trials;Journal of Endocrinological Investigation;2023-11-03

4. Use of vitamin D with anti-osteoporotic drugs: are available clinical trials telling us the whole story?;Endocrine;2023-10-10

5. Executive summary: Italian guidelines for diagnosis, risk stratification, and care continuity of fragility fractures 2021;Frontiers in Endocrinology;2023-04-18